The FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849-61.
2.
Feher MD, Caslake M., Foxton J., Cox A., Packard CJAtherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395-9.
3.
Diabetes Atherosclerosis InterventionStudy Investigators.Effects of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
4.
Madej A., Okopien B., Kowalski J. et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinaemia IIB. Int J Clin Pharmacol Ther1998;36:345-9.
5.
Keating GM, Ormrod D.: Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs2002, 62:1909-44.
6.
Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ1998;316:823-8.
7.
Colhoun HM, Betteridge DJ, Durrington PN et al. (Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V. Fuller JH,) on behalf of the CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
8.
Collins R., Armitage J., Parish S. et al. for the Heart Protection Study Collaborative Group.MRC/BHF heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
9.
Rubins HB, Robins SJ, Collins D. et al. (Fye CL, Anderson JW, Elam BM, Faas FH, Linares E., Schaefer EJ, Schectman G., Wilt TJ, Wittes J.): Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density lipoprotein cholesterol Intervention Trial study group. N Engl J Med1999;341:410-18.
10.
Davidson MHCombination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol2002;90:50K-60K.
11.
Elkeles RS, Diamond JR, Poulter C. et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care1998;21:641-8.
12.
Frick MH, Elo O., Haapa K. et al. (Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V and others): Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety treatment, changes in risk factors and incidence of coronary heart disease. N Eng J Med1987;317:1237-45.
13.
Koskinen P. , Mänttäri M., Manninen V., Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992;15:820-5.
